BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,628,161 | -12.4% | 141,445 | +5.0% | 0.02% | -17.4% |
Q2 2023 | $10,996,949 | +28.5% | 134,717 | +16.8% | 0.02% | +15.0% |
Q1 2023 | $8,560,191 | -9.6% | 115,382 | +0.5% | 0.02% | -23.1% |
Q4 2022 | $9,471,886 | +31.1% | 114,769 | +351.2% | 0.03% | +13.0% |
Q3 2022 | $7,224,000 | -7.2% | 25,436 | +13.3% | 0.02% | -32.4% |
Q2 2022 | $7,783,000 | -14.1% | 22,452 | +7.3% | 0.03% | -5.6% |
Q1 2022 | $9,065,000 | -3.3% | 20,934 | +8.9% | 0.04% | -2.7% |
Q4 2021 | $9,375,000 | +17.0% | 19,219 | +16.3% | 0.04% | -5.1% |
Q3 2021 | $8,010,000 | +103.9% | 16,531 | +89.5% | 0.04% | +85.7% |
Q2 2021 | $3,929,000 | +1055.6% | 8,725 | +881.4% | 0.02% | +950.0% |
Q1 2021 | $340,000 | +86.8% | 889 | +55.4% | 0.00% | +100.0% |
Q4 2020 | $182,000 | +40.0% | 572 | +9.2% | 0.00% | 0.0% |
Q3 2020 | $130,000 | -7.8% | 524 | -1.9% | 0.00% | -50.0% |
Q2 2020 | $141,000 | – | 534 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |